Similar to other protein kinase inhibitors, MAPK14 inhibitors mostly function through competitive inhibition at the ATP-binding site. There are two types of these competitive inhibitors: Type 1, which bind in the active DGF-in conformation (e.g., compound SB 203580), and Type 2, which bind in the inactive DFG-out conformation (e.g., compound Birb 796). The two binding modes differ in the orientation of the DFG motif within the ATP pocket. Many different p38 inhibitors have been, or are currently being, investigated in phase I or II clinical trials, including Birb 796 and VX-745, but none have been recommended for use, mostly due to high toxicity or lack of significant efficacy. Since existing p38 inhibitors have been artificially synthesized, their side effects are unknown until human clinical trials, which is why even though they may work very well during in-vitro trials or even in-vivo animal models, they end up failing at the clinical trials. Development of new drugs is a very long and expensive process, so in this project we propose to repurpose existing FDA-approved drugs to find effective, non-toxic p38 inhibitors with already known side effects. FDA drug repurposing significantly expedites the drug discovery process, delivering safer yet effective treatments to patients in a much timelier manner.